Compare GITS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GITS | APRE |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | South Korea | United States |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.7M |
| IPO Year | N/A | 2019 |
| Metric | GITS | APRE |
|---|---|---|
| Price | $1.54 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 23.4K | ★ 150.1K |
| Earning Date | 11-20-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.41 |
| 52 Week High | $7.09 | $1.49 |
| Indicator | GITS | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 42.04 |
| Support Level | $1.42 | $0.41 |
| Resistance Level | $2.87 | $0.81 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 40.47 | 52.63 |
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.